A Young Woman With Recurrent Gestational Hypercalcemia and Acute Pancreatitis Caused by CYP24A1 Deficiency. by Woods, Gina N et al.
UC San Diego
UC San Diego Previously Published Works
Title
A Young Woman With Recurrent Gestational Hypercalcemia and Acute Pancreatitis 
Caused by CYP24A1 Deficiency.
Permalink
https://escholarship.org/uc/item/8cq5v00z
Journal
Journal of bone and mineral research : the official journal of the American Society for 
Bone and Mineral Research, 31(10)
ISSN
0884-0431
Authors
Woods, Gina N
Saitman, Alec
Gao, Hanlin
et al.
Publication Date
2016-10-01
DOI
10.1002/jbmr.2859
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A Young Woman With Recurrent Gestational
Hypercalcemia and Acute Pancreatitis Caused by
CYP24A1 Deficiency
Gina N Woods,1 Alec Saitman,2 Hanlin Gao,3 Nigel J Clarke,4 Robert L Fitzgerald,2 and Nai-Wen Chi1
1Department of Medicine, University of California, San Diego, CA, USA
2Department of Pathology, University of California, San Diego, CA, USA
3Fulgent Diagnostics, Temple City, CA, USA
4Mass Spectrometry R&D Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
ABSTRACT
The CYP24A1 gene encodes amitochondrial 24-hydroxylase that inactivates 1,25(OH)2D. Loss-of-functionmutations in CYP24A1 cause
hypercalcemia, nephrolithiasis and nephrocalcinosis. We describe a woman with CYP24A1 deficiency and recurrent gestational
hypercalcemia. Her first pregnancy, at age 20, resulted with the intrauterine demise of twin fetuses. Postpartum, she developed severe
hypercalcemia (14mg/dL), altered mental status, and acute pancreatitis. Her PTH was suppressed (6 pg/mL) and her 1,25(OH)2D was
elevated (165 and 195pg/mLonpostpartumday1 and 5, respectively). Betweenone and threemonths postpartum,her serumcalcium
decreased from 11.4 to 10.2mg/dLwhile her 1,25(OH)2D level decreased from 83 to 24pg/mL. Her 24-hour urine calciumwas 277mg.
Six months postpartum, she became pregnant again. At 14 weeks, her albumin-corrected calcium level was 10.4mg/dL and her 1,25
(OH)2D level exceeded 200pg/mL. To establish the diagnosis of CYP24A1 deficiency, we showed her 24,25(OH)2D level to be
undetectable (<2 ng/mL). Exon sequencing of the CYP24A1 gene revealed a homozygous, 8-nucleotide deletion in exon 8, causing an
S334V substitution and premature termination due to a frame shift (c.999_1006del, p.Ser334Valfs9). To prevent hypercalcemia, she
was advised to discontinue prenatal vitamins, avoid sun exposure and calcium-rich foods, and start omeprazole and a calcium binder
(250mg K-Phos-neutral with meals). Despite thesemeasures, both hypercalcemia (11.5mg/dL) and acute pancreatitis recurred. Labor
was induced and a healthy, normocalcemic boy was delivered. In the absence of lactation, maternal hypercalcemia resolved within
2months. This report shows that CYP24A1-deficient subjectsmay be normocalcemic at baseline. Hypercalcemiamay be unmasked by
pregnancy through the routine use of calciferol-containing prenatal vitamins, increased 1-alpha hydroxylation of VitD by the placenta
and maternal kidney, and production of PTHrP by the uteroplacental unit. CYP24A1 deficiency should be considered in patients with
unexplained vitamin D-mediated hypercalcemia. © 2016 American Society for Bone and Mineral Research.
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Introduction
The CYP24A1 gene encodes a mitochondrial 24-hydroxylasethat metabolizes both 25OHD and 1,25(OH)2D. The induc-
tion of CYP24A1 gene expression by both hypercalcemia and
1,25(OH)2D provides a safeguard against vitamin D-induced
hypercalcemia.(1) Conversely, inactivating mutations in CYP24A1
can cause hypercalcemia. Following the introduction of
vitamin D fortification of infant formula in Great Britain in the
1950s, Lightwood described an epidemic of idiopathic infantile
hypercalcemia and postulated supranormal sensitivity to
vitamin D as the culprit.(2,3) Subsequently, Schlingman identified
loss-of-function mutations in CYP24A1 in a kindred of idiopathic
infantile hypercalcemia.(4) CYP24A1 deficiency has since been
reported to cause hypercalcemia in all age groups.(5)
During pregnancy, 25OHD 1-alpha hydroxylase is expressed
by the placenta and upregulated in thematernal kidney, leading
to a physiological doubling of maternal 1,25(OH)2D levels.
(6)
Because most prenatal vitamin supplements provide 400 IU/day
of vitamin D, one might expect pregnancy to increase the
phenotypic penetrance of CYP24A1 deficiency. However, only
two cases of gestational hypercalcemia have been attributed
to CYP24A1 deficiency.(7,8) Herein we report the case of a
20-year-old woman with a homozygous inactivating CYP24A1
mutation who developed recurrent gestational hypercalcemia
and pancreatitis.
Patient and Methods
Case report
A 20-year-old primipara was referred to our medical center at
23 weeks of gestation because of severe maternal hypertension
and intrauterine growth restriction of twin fetuses. After the
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demise of both fetuses, labor was induced at 26 weeks.
Immediately postpartum, the patient’s mental status became
altered and hypercalcemia was noted at 14mg/dL (albumin
3.0 g/dL). She was treated with saline infusion and one dose
of subcutaneous calcitonin (4 U/kg). Biochemical workup
revealed a suppressed PTH (6 pg/mL), an undetectable PTHrP
(<2.8 pmol/L), a 25OHD of 45 ng/mL, and elevated 1,25(OH)2D
levels (165 and 195 pg/mL on postpartum days 1 and 5,
respectively). A subsequent review of her outside medical
records revealed the presence of hypercalcemia (12.3mg/dL) at
12 weeks of gestation that had not been further evaluated.
In addition to altered mental status, the patient developed
fevers, tachycardia, and epigastric pain. Acute pancreatitis was
diagnosed on postpartum day 3 with a serum lipase level of
1416U/L. Her triglyceride levels were 140mg/dL. An abdominal
CT scan revealed an edematous pancreas and moderate ascites
but no evidence of cholelithiasis (Fig. 1). Also noted was
extensive mesenteric and omental thickening that, along with
an abrupt drop in serum calcium (Fig. 2), suggested saponifica-
tion associated with pancreatitis (Fig. 1).
Before the pregnancy, the patient weighed 41.3 kg (BMI
17.8 kg/m2) and did not receive regular medical care. She has
had hypertension since childhood. Her medications during
pregnancy consisted of a prenatal vitamin (discontinued
postpartum) and labetalol (200mg twice daily). She had no
prior history of hypercalcemia, kidney stones, fractures,
pancreatitis, or alcohol use. Renal ultrasound revealed simple
cysts bilaterally but no nephrolithiasis or nephrocalcinosis. She
was born in Mexico; her parents were from the same town but
not known to be blood-related. There was no family history of
calcium disorders, kidney stones, or pancreatitis.
A search for potential causes of the patient’s vitamin D-
mediated hypercalcemia revealed an angiotensin-converting
enzyme level of 8 U/L (reference range 9 to 13U/L) and a positive
QuantiFERON-TB Gold In-Tube test (Cellestis Inc., Valencia, CA,
USA) test. Her ascites fluid showed a serum-ascites albumin
gradient of 0.3 g/dL and tested negative in bacterial and
mycobacterial cultures as well as acid-fast bacilli (AFB) stains. Her
chest radiograph revealed a calcified granuloma (5mm) in the
right upper lobe. This was redemonstrated by a chest CT, which
unexpectedly also revealed multiple pulmonary emboli but no
mediastinal lymphadenopathy, active pulmonary tuberculosis,
sarcoidosis, or malignancy. A bone marrow biopsy revealed
normal cellularity and hematopoiesis, without evidence of
lymphoma, granuloma, mycobacteria, or growth in AFB culture.
Under the suspicion that sarcoidosis might be responsible for
her hypercalcemia (12.0mg/dL), she was given one 40-mg dose
of prednisone on postpartum day 26. The next day, her serum
calcium levels remained unchanged. She was discharged on
postpartum day 28 with instructions to continue an anticoagu-
lant and amlodipine. Between 1 and 3 months postpartum, her
serum calcium and 1,25(OH)2D levels decreased from 11.4 to
10.2mg/dL and from 83 to 24 pg/mL, respectively. Over the
ensuing 3months, her serum calcium remained between 10.0 to
10.2mg/dL and her 24-hour urine calcium was 277mg.
Results
The patient became pregnant again 6 months postpartum
and resumed prenatal vitamin supplementation. At 14 weeks
of gestation, her calcium was 10.0mg/dL (albumin 3.5 g/dL)
and her 1,25(OH)2D level exceeded 200 pg/mL. To establish
the diagnosis of CYP24A1 deficiency, we found her 24,25(OH)2D
level (both D2 and D3) to be below the detection limit of
2 ng/mL, whereas a concurrent 25OHD level was 53 ng/mL.
Exon sequencing of the CYP24A1 gene in peripheral leucocytes
revealed a homozygous, 8-nucleotide (nt) deletion (c.999_1006del,
p.Ser334Valfs9) in exon 8, causing an S334V substitution and
premature termination due to a frame shift (Fig. 3).
Upon confirmation of CYP24A1 deficiency at 22 weeks of
gestation, the patient was advised to discontinue prenatal
vitamins and to minimize sun exposure and calcium-rich foods.
To reduce intestinal calcium absorption, she was prescribed
omeprazole (20mg daily) and phosphate (250mg of K-Phos
Neutral with each meal, Beach Pharmaceuticals, Tampa, FL).
Fig. 1. Abdominal CT scan showing an edematous pancreas, simple
ascites, and renal cysts without evidence of nephrocalcinosis.
Fig. 2. Serum levels of calcium, 25OHD, and 1,25(OH)2D during (A) first
pregnancy and (B) second pregnancy.
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Despite these measures, her calcium levels rose to 11.5mg/dL
(albumin 3.5 g/dL) at 33 weeks of gestation, when severe
epigastralgia led to the diagnosis of acute pancreatitis. Her
pancreas was edematous and enlarged on ultrasound. Her
amylase and lipase levels peaked at 1688U/L and 4440U/L,
respectively. Because neither cholelithiasis nor dilatation of the
biliary tree was found on ultrasound or magnetic resonance
cholangiopancreatography, we attributed the pancreatitis to
hypercalcemia.
The patient received aggressive saline infusion and one dose
of subcutaneous calcitonin for her pancreatitis and hypercalce-
mia. Because of worsening hypertension, labor was induced at
34 weeks. The male newborn weighed 1786 g (14.5th percen-
tile), had a cord blood calcium level of 9.2mg/dL, and showed no
signs of hypercalcemia or hypocalcemia during the 12 days
of hospitalization. Comparisons of maternal serum (8 days
antepartum) with cord blood showed a transplacental gradient
of 30 to 14 ng/mL for 25OHD, and 199 to 39 pg/mL for 1,25
(OH)2D. The patient was discharged on postpartum day 7 with a
serum calcium level of 10.7mg/dL and 1,25(OH)2D level of
87 pg/mL. She self-injected calcitonin (100mg) on postpartum
days 10, 13, and 18, while her calcium decreased from 12 to
9.8mg/dL. Her calcium level was 10.0mg/dL (albumin 4.5 g/dL)
6 months postpartum.
Discussion
CYP24A1 mutations can cause hypercalcemia, nephrolithiasis,
and nephrocalcinosis that manifest during infancy(4,9) or
adulthood.(5,7,8,10) This case report describes a CYP24A1-deficient
young woman with gestational hypercalcemia during two
consecutive pregnancies, each confoundedby acute pancreatitis,
a complication not previously attributed to CYP24A1 mutations.
The pathogenic 8-nt deletion (c.999_1006del) has not been
reported in CYP24A1-related hypercalcemia. This deletion is
expected to abolish the 24-hydroxylase activity of CYP24A1
because the resulting premature stop codon is predicted to
trigger degradation of the mRNA(11) and the deletion removes
the heme-binding domain (aa 455–464) critical to enzymatic
activity.(12)
A plausible explanation for the limited penetrance of our
patient’s biallelic CYP24A1 mutation is that she has consistently
avoided sun exposure since age 4 years, when the exposure was
noted to cause a rash. Alternatively, she might have been
protected from vitamin D-mediated hypercalcemia by compen-
satory mechanisms that downregulate 1,25(OH)2D production
or upregulate its degradation through CYP24A1-independent
pathways that have been proposed by mouse models of
CYP24A1 deficiency.(13)
During pregnancy and peripartum, several factors could
synergize to unmask the hypercalcemic effect of CYP24A1
deficiency. These include increased calciferol intake from
prenatal vitamins, increased activation of 25OHD by the
placenta and maternal kidney, the cessation of transplacental
calcium flux at delivery,(14,15) and the production of PTHrP by the
placenta(16) and lactating mammary gland.(17) We expect these
gestation-specific hypercalcemic factors to be poorly tolerated
in the CYP24A1-deficient state, where the already-suppressed
PTH levels offer no room for further suppression.
Our patient shared several gestational complications with
pregnant women who have PTH-mediated hypercalcemia.
These include worsening hypertension, peripartum hypercalce-
mic crisis, pancreatitis (both pregnancies), and fetal demise (first
pregnancy).(14,18) Although not previously linked to CYP24A1
deficiency, the pancreatitis in our patient was likely attributable
to hypercalcemia because she did not have the usual risk factors
such as cholelithiasis, hypertriglyceridemia, or alcohol use.
Maternal PTH-mediated hypercalcemia is known to cause
transient neonatal hypocalcemia.(19) Our patient’s baby was free
from hypocalcemia presumably because of our multipronged
approach to minimize gestational hypercalcemia. The baby was
also free from hypercalcemia, in line with the typically recessive
nature of CYP24A1-related hypercalcemia.(4) The normal 1,25
(OH)2D level in the cord blood (39 ng/mL) despite a maternal
level of 199 ng/mLwas also in keepingwith the limited placental
transfer of this vitamin.(20)
The calcemic effect of breastfeeding has not been investi-
gated in CYP24A1-deficient mothers. By stimulating mammary
production of PTHrP, lactation often induces mild hypercalce-
mia(21) and occasionally causes symptomatic hypercalcemia.(22)
We advised our patient to stop breastfeeding after colostrum
production because of the concern that lactation-induced
hypercalcemia might exacerbate ongoing hypercalcemia and
acute pancreatitis. Indeed, her PTHrP level on postpartum day 4
was found to be 3.4 pmol/L, the upper limit of the normal range.
It is noteworthy that during the resolution of hypercalcemia
after each pregnancy, our patient transitioned through a phase
when hypercalcemia was accompanied by 1,25(OH)2D levels
that fell within the reference range (20 to 79 pg/mL) (Fig. 2). An
analogous transitional phase has been observed in sarcoid
patients with hypercalcemia, where glucocorticoid treatment
normalizes 1,25(OH)2D levels approximately 1 week before the
resolution of hypercalcemia (3 to 7 versus 12 to 15 days).(23) This
illustrates the caveat that normal levels of 1,25(OH)2D do not
exonerate this hormone as the cause of hypercalcemia.
Our patient received one 40-mg dose of prednisone just
before leaving the hospital following the first pregnancy, when
sarcoidosis was presumed to cause her hypercalcemia. Although
this trial of glucocorticoids was of inadequate duration to
demonstrate a treatment effect, or lack thereof, available
literature suggests that CYP24A1-associated hypercalcemia
does not respond to glucocorticoids.(10,24)
Historically, the cause of 1,25(OH)2D-mediated hypercalcemia
remains unidentified in up to 18% of cases.(25) Given the recent
realization that many of these cases are caused by CYP24A1
Fig. 3. The intron-exon structure of the CYP24A1 locus on chromosome
20. Deletion of the 8 nucleotides highlighted in exon 8 (c.999_1006del)
causes a valine substitution of Ser334 followed by a premature stop
codon (p.Ser334Valfs9). This frame shift deletion corresponds to a
minor CYP24A1 allele (SNP ID: rs770055617, http://www.ncbi.nlm.nih.
gov/snp) with an apparent allele frequency of <0.0005. CYP24A1
homozygosity in the patient was confirmed by additional deletion/
duplication analyses (data not shown).
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mutations,(26) measurement of plasma 24,25(OH)2D level and its
ratio over 25OHD should be included in the evaluation of
vitamin D-mediated hypercalcemia. A low ratio (<0.04 in our
case) suggests impaired vitamin D catabolism and may warrant
sequencing of the CYP24A1 gene. As reported previously(7,8)
and herein, hypercalcemia from CYP24A1 deficiency may be
unmasked by the physiological changes of pregnancy. It is
therefore important to establish a pregnancy- or trimester-
specific reference range for 24,25(OH)2D and its ratio over
25OHD.
In summary, hypercalcemia caused by CYP24A1 deficiency
maymanifest only during pregnancy inwomenwithout baseline
hypercalcemia or nephrocalcinosis. Potential complications in
pregnancy may include maternal hypertension, acute pancrea-
titis, and fetal demise. CYP24A1 deficiency should be considered
in patients with otherwise unexplained vitamin D-mediated
hypercalcemia, including those with “inappropriately normal”
1,25(OH)2D levels or subnormal levels of 24,25(OH)2D. Behav-
ioral management of CYP24A1-related hypercalcemia includes
the avoidance of sun exposure, vitamin D, and dietary calcium.
Future studies will investigate the indications and modalities
of pharmacological management during pregnancy and the
safety of breastfeeding.
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